Exit / M&A
Spinifex Pharmaceuticals to be Acquired by Novartis - PR Newswire
Chronic-pain drug developer Spinifex Pharmaceuticals has agreed to be bought by Novartis for US$200 million upfront plus undisclosed milestones, centred on its lead candidate EMA401.